Compare AUGO & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUGO | PTCT |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.5B |
| IPO Year | 2009 | 2006 |
| Metric | AUGO | PTCT |
|---|---|---|
| Price | $78.47 | $62.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 16 |
| Target Price | ★ $102.96 | $97.94 |
| AVG Volume (30 Days) | 774.1K | ★ 1.0M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $74.24 | N/A |
| Revenue Next Year | $18.57 | $9.47 |
| P/E Ratio | ★ N/A | $69.66 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $29.11 | $58.80 |
| 52 Week High | $110.32 | $90.87 |
| Indicator | AUGO | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 46.72 |
| Support Level | $71.04 | $61.95 |
| Resistance Level | $91.61 | $72.86 |
| Average True Range (ATR) | 4.38 | 1.99 |
| MACD | -0.68 | 0.33 |
| Stochastic Oscillator | 3.14 | 61.44 |
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.